JP2019530724A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530724A5 JP2019530724A5 JP2019520406A JP2019520406A JP2019530724A5 JP 2019530724 A5 JP2019530724 A5 JP 2019530724A5 JP 2019520406 A JP2019520406 A JP 2019520406A JP 2019520406 A JP2019520406 A JP 2019520406A JP 2019530724 A5 JP2019530724 A5 JP 2019530724A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- hydrogen
- aryl
- heterocyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims 64
- 229910052739 hydrogen Inorganic materials 0.000 claims 54
- 239000001257 hydrogen Substances 0.000 claims 50
- 125000000623 heterocyclic group Chemical group 0.000 claims 48
- 125000003118 aryl group Chemical group 0.000 claims 47
- 125000000547 substituted alkyl group Chemical group 0.000 claims 39
- 125000001072 heteroaryl group Chemical group 0.000 claims 37
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 34
- 125000002837 carbocyclic group Chemical group 0.000 claims 33
- 125000003710 aryl alkyl group Chemical group 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 125000003342 alkenyl group Chemical group 0.000 claims 24
- 150000002148 esters Chemical class 0.000 claims 20
- 239000000651 prodrug Substances 0.000 claims 20
- 229940002612 prodrug Drugs 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 20
- 150000002431 hydrogen Chemical class 0.000 claims 16
- -1 pyrrolidino, phenyl Chemical group 0.000 claims 16
- 125000001424 substituent group Chemical group 0.000 claims 16
- 229910052717 sulfur Inorganic materials 0.000 claims 13
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 125000004429 atom Chemical group 0.000 claims 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 9
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000010706 fatty liver disease Diseases 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 101000885387 Homo sapiens Serine/threonine-protein kinase DCLK2 Proteins 0.000 claims 5
- 102100039775 Serine/threonine-protein kinase DCLK2 Human genes 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 108091000080 Phosphotransferase Proteins 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 102000020233 phosphotransferase Human genes 0.000 claims 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 2
- 125000003627 8 membered carbocyclic group Chemical group 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims 1
- 101100459319 Arabidopsis thaliana VIII-2 gene Proteins 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023665 Barrett oesophagus Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 1
- 208000026589 Wolman disease Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000002394 glycogenic effect Effects 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical group CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000003079 salivary gland Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409457P | 2016-10-18 | 2016-10-18 | |
| US62/409,457 | 2016-10-18 | ||
| PCT/US2017/057126 WO2018075608A1 (en) | 2016-10-18 | 2017-10-18 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019530724A JP2019530724A (ja) | 2019-10-24 |
| JP2019530724A5 true JP2019530724A5 (cg-RX-API-DMAC7.html) | 2020-11-26 |
| JP7086948B2 JP7086948B2 (ja) | 2022-06-20 |
Family
ID=62018969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520406A Active JP7086948B2 (ja) | 2016-10-18 | 2017-10-18 | ピリミド－ジアゼピノンキナーゼ骨格化合物およびｄｃｌｋ１／２媒介性障害の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11028089B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3528814B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7086948B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017346845B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3040173A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018075608A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6968819B2 (ja) * | 2016-04-07 | 2021-11-17 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッドDana−Farber Cancer Institute, Inc. | ピリミド−ジアゼピノンキナーゼ骨格化合物およびｐｉ３ｋ媒介性障害の治療方法 |
| US11279707B2 (en) | 2017-12-22 | 2022-03-22 | Dana-Farber Cancer Institute, Inc. | NEK inhibitors and methods of use |
| CN114728009B (zh) * | 2019-08-08 | 2024-09-03 | 李晓祥 | 预防或治疗与组织损伤相关的疾病和紊乱 |
| EP4103182A4 (en) * | 2020-02-14 | 2024-02-21 | Salk Institute for Biological Studies | INHIBITORS OF ULK1/2 AND METHODS OF USE THEREOF |
| EP4229061A4 (en) * | 2020-10-14 | 2024-09-25 | Ranok Therapeutics (Hangzhou) Co. Ltd. | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION |
| US20240254138A1 (en) * | 2021-03-09 | 2024-08-01 | Janssen Pharmaceutica Nv | Tricyclic pyrimidines as cyclin-dependent kinase 7 (cdk7) inhibitors |
| CN115707469B (zh) * | 2021-08-19 | 2024-07-02 | 首都医科大学附属北京朝阳医院 | Dclk1抑制剂和tki在制备肺腺癌药物中的应用 |
| CN114478539B (zh) * | 2022-02-09 | 2024-02-02 | 中国人民解放军海军军医大学 | 一种新型dclk1抑制剂及其制备方法和应用 |
| CN115969978A (zh) * | 2022-10-27 | 2023-04-18 | 首都医科大学附属北京朝阳医院 | Dclk1及il6/stat3通路抑制剂在治疗三阴性乳腺癌中的应用 |
| CN115814094B (zh) * | 2023-01-04 | 2024-04-02 | 暨南大学附属第一医院（广州华侨医院） | Dclk抑制剂在制备治疗脊髓损伤的药物中的应用 |
| CN116375713B (zh) * | 2023-03-07 | 2024-11-19 | 中国人民解放军海军军医大学 | 一种dclk1蛋白降解靶向嵌合体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3828185B1 (en) | 2009-01-06 | 2024-11-20 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| WO2012153796A1 (ja) * | 2011-05-10 | 2012-11-15 | 協和発酵キリン株式会社 | ピリミドジアゼピノン化合物 |
| WO2014160430A1 (en) * | 2013-03-13 | 2014-10-02 | Georgetown University | Small molecule lrrk2 and erk5 inhibitors |
| WO2014145909A2 (en) * | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone compounds and methods of treating disorders |
| WO2015117083A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
| WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| WO2016022902A1 (en) * | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
| US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6815318B2 (ja) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| CN107151250B (zh) | 2016-03-04 | 2020-03-27 | 安徽省新星药物开发有限责任公司 | 嘧啶类七元环化合物、其制备方法、药用组合物及其应用 |
-
2017
- 2017-10-18 AU AU2017346845A patent/AU2017346845B2/en active Active
- 2017-10-18 JP JP2019520406A patent/JP7086948B2/ja active Active
- 2017-10-18 CA CA3040173A patent/CA3040173A1/en active Pending
- 2017-10-18 WO PCT/US2017/057126 patent/WO2018075608A1/en not_active Ceased
- 2017-10-18 EP EP17862888.9A patent/EP3528814B1/en active Active
- 2017-10-18 US US16/343,102 patent/US11028089B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530724A5 (cg-RX-API-DMAC7.html) | ||
| JP2019094345A5 (cg-RX-API-DMAC7.html) | ||
| TWI457337B (zh) | 呋呫基苯并咪唑 | |
| ES2975302T3 (es) | Compuesto de propionato de piridil imidazobenzodiazepina y síntesis y uso del mismo | |
| JP2019529444A5 (cg-RX-API-DMAC7.html) | ||
| CN111836814A (zh) | 稠环化合物、其制备方法及用途 | |
| RU2019129727A (ru) | Применения пиримидопиримидинонов в качестве ингибиторов sik | |
| JP2019510787A5 (cg-RX-API-DMAC7.html) | ||
| JP2016505586A5 (cg-RX-API-DMAC7.html) | ||
| JP2007508238A5 (cg-RX-API-DMAC7.html) | ||
| RU2019100164A (ru) | Гетероциклическое соединение, используемое как ингибитор fgfr | |
| JP2019531346A5 (cg-RX-API-DMAC7.html) | ||
| JP2007515419A5 (cg-RX-API-DMAC7.html) | ||
| KR20110013411A (ko) | (ｆ-19)-표지된 ｌ-글루탐산 및 ｌ-글루타민 유도체 (ⅲ), 그의 용도 및 그의 수득 방법 | |
| AU2008216106C1 (en) | Cancer treatment method | |
| JP2005119987A (ja) | アシルスルホンアミド誘導体 | |
| JP2018507230A5 (cg-RX-API-DMAC7.html) | ||
| ES2911183T3 (es) | Compuesto para inhibir selectivamente quinasas y uso del mismo | |
| DK2767538T3 (en) | TETRANDRINDERIVATER with substituted 5-CARBON, PRODUCTION PROCESS AND USE THEREOF | |
| JP2021512075A (ja) | 一過性受容体電位ａ１イオンチャネルの阻害 | |
| JP2009528997A5 (cg-RX-API-DMAC7.html) | ||
| JP2020534266A5 (cg-RX-API-DMAC7.html) | ||
| RU2013107759A (ru) | Производные оксадиазола и пиридазина, их получение и применение в терапии | |
| MX2009002905A (es) | Derivados de 3-amino-piridina para el tratamiento de trastornos metabolicos. | |
| JPWO2022029138A5 (cg-RX-API-DMAC7.html) |